Description  Claims  Drawing  Cited references 

WO2011098520A1   [0013]  [0063] 
WO2011098520A1A   [0063] 
US4522811A   [0095] 

Nat. Med.   [0005] 
Drug Dev. Res.   [0005] 
Br. J. Cancer   [0005] 
Ann. Oncol.   [0005] 
Cancer Lett.   [0005] 
JEM   [0005] 
Immunol and Cell Biol   [0005] 
Cancer Immunol Immunother   [0005] 
Cancer Cell   [0006] 
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.   [0011] 
J Clin Immunol   [0012] 
Mahipal A. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Papadopoulos KP1   [0012] 
Getting TRAIL back on track for cancer therapy.   [0012] 
Sequences of Proteins of Immunological Interest   [0028]  [0034]  [0037]  [0042]  [0043] 
J. Biol Chem Vol.   [0043] 
Nature Biotech   [0043] 
Cancer Res   [0045] 
J Immunol   [0045] 
mAbs   [0045] 
PNAS   [0045] 
JBC   [0045] 
Cancer Res   [0045] 
Advan. Enzyme Regul.   [0045] 
J Immunol   [0045] 
Biodrugs   [0045] 
Journal of Immunological Methods   [0046] 
Selection and identification of single domain antibody fragments from camel heavy-chain antibodies   [0068] 
Single-domain antibodies as building blocks for novel therapeutics   [0069] 
Single-domain antibodies as building blocks for novel therapeutics   [0070] 
Domain antibodies: proteins for therapy   [0071] 
Antibody evolution beyond Nature   [0071] 
Molecular Cloning: A Laboratory Manual   [0098] 
accordance with the definitions of Kabat Sequences of Proteins of Immunological Interest   [0103] 
Mol. Biol.   [0103] 
Nature   [0103] 
Nature   [0106] 
Annual Rev Biochem   [0106] 
Science   [0109] 
Proteins, Structures and Molecular Principles   [0110] 
Introduction to Protein Structure   [0110] 
Nature   [0110] 
Adv. Drug Res.   [0112] 
TINS   [0112] 
J. Med. Chem.   [0112] 
Ann. Rev. Biochem.   [0112]